Results 181 to 190 of about 42,157 (238)

Aquaporin 3 Promoter Polymorphisms Reduce Gene Expression and Associate Altered Autophagy‐Related Gene Signatures With Atopic Dermatitis Susceptibility

open access: yesExperimental Dermatology, Volume 35, Issue 9, September 2026.
ABSTRACT Genome‐wide association studies (GWAS) have uncovered multiple loci associated with atopic dermatitis (AD), although mechanistic understanding remains limited. Here, we examine a risk variant in the aquaporin 3 (AQP3) promoter and propose a mechanistic link between genotype to altered autophagy, skin barrier integrity, and wound healing in AD.
Yi Ying Eliza Lim   +5 more
wiley   +1 more source

Allergy in Latin America: Great Need, Even Greater Opportunity. [PDF]

open access: yesClin Exp Allergy
Borzutzky A   +3 more
europepmc   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

open access: yesInternational Journal of Dermatology, Volume 65, Issue 9, Page 1846-1855, September 2026.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo   +11 more
wiley   +1 more source

When to consider an inborn error of immunity: clues for physicians

open access: yesInternal Medicine Journal, Volume 56, Issue 9, Page 1488-1499, September 2026.
Abstract The term inborn errors of immunity (IEIs) refers to the rapidly expanding group of genetic disorders causing dysregulation of the immune system. With improved genetic testing in recent years, the number of defined IEIs and their range of phenotypic presentations has grown vastly, with more than 550 IEIs now described.
Meera Thangarajah, Lucinda J. Berglund
wiley   +1 more source

Differential Effects of Benralizumab and Mepolizumab on Pro‐Resolving Mediators

open access: yes
Allergy, Volume 81, Issue 9, Page 3377-3383, September 2026.
Jaime Bernaola   +14 more
wiley   +1 more source

Update on biologic and small molecules treatments in pediatric allergic diseases

open access: yesPediatric Allergy and Immunology, Volume 37, Issue 9, September 2026.
This graphical abstract summarizes key targets, mechanisms of action, and indications of biologic and small molecules treatments in pediatric allergic diseases.abbreviations : BAS, basophil; BTK, Bruton tyrosine kinase; cDC, conventional dendritic cell; IgE, immunoglobulin E; FCER1, high affinity IgE receptor; IL, interleukin; IL4R, IL4 receptor; JAK ...
Herman T. den Dekker   +10 more
wiley   +1 more source

Paediatric perioperative hypersensitivity reactions: Analysis of the French GERAP network database

open access: yesPediatric Allergy and Immunology, Volume 37, Issue 9, September 2026.
Graphical abstract of the pediatric perioperative hypersensitivity reactions recorded in the GERAP network datbase between 1997 and 2024. Abstract Background Perioperative hypersensitivity (POH) reactions are rare but potentially life‐threatening and remain poorly characterised in children.
Mertes Paul Michel   +104 more
wiley   +1 more source

Triggers, clinical spectra and outcomes of pediatric anaphylaxis in a tertiary center: impact of comorbidities and cofactors on severity. [PDF]

open access: yesAllergy Asthma Clin Immunol
Keser-Ozturk N   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy